336 results about "Endocrine secretion" patented technology

The invention discloses a 3D intestinal organ differentiation method based on human pluripotent stem cells and an induction culture medium and application thereof, and relates to the technical field of stem cells. According to a culture medium formula combination, intestinal organs can be differentiated into various cell types such as epithelial cells, neuroendocrine cells and endothelial cells; the method is a key mark for successful differentiation and functional maturation of intestinal organs. According to the 3D intestinal organ differentiation method disclosed by the invention, histological structures such as intestinal crypts are differentiated from intestinal organs generated by differentiation, and the intestinal organs can creep in a maintenance stage, so that the intestinal organs are changed from structural bionics to functional simulation, and the significance of the 3D intestinal organ differentiation method is far better than that of pure morphological simulation. Through a systematic culture medium formula, a clear operation process and a multi-stage induction strategy, the 3D intestinal organ with structural integrity, cell diversity and functional activity is successfully constructed, and the system provides an efficient, reliable and extensible in-vitro model platform for intestinal biological research and related application.

The invention relates to the field of animal consumer goods, and particularly discloses application of glucan in preparation of animal products for relieving pet stress syndromes. Pet experiments find that beta-1, 3 / alpha-1, 3-glucan can improve the stress syndromes of the indoor cats, specifically, abnormal behaviors of the cats are corrected, and abnormity of multiple systems of organisms such as the immune system, the endocrine system and the urinary system is improved. And when the method is applied to pets, the life quality of the pets can be remarkably improved, more emotional support is provided for pet owners, and the method has practical popularization and application values.

The invention relates to the technical field of data analysis, can be applied to business system platforms of financial science and technology, medical treatment and health and the like, and discloses a human body state characteristic value analysis method, device and equipment and a medium. Performing system state analysis on an endocrine system, a circulatory system and a respiratory system of the user according to the physical examination data to obtain a system state characteristic value set, constructing a physiological index vector and a disease course characteristic vector according to the physical examination data, and constructing a complication incidence matrix according to case data; performing complication association analysis on the user according to the physiological index vector, the disease course feature vector and the complication association matrix to obtain a complication feature value, analyzing a criticality feature value of the user according to a system state feature value set and the complication feature value to obtain a hazard feature value set, and performing weighted summation on the hazard feature value set to obtain a complication feature value set; and obtaining a human body state characteristic value. And the accuracy of human body state characteristic value analysis is improved.

The present disclosure relates to the field of nuclear imaging and therapy, and more specifically to high purity copper radiotracer compositions useful in imaging, such as positron emission tomography (PET) and single-photon emission computerized tomography (SPECT), and therapy. More specifically, the present disclosure relates to novel compositions useful in imaging and treatment of conditions such as prostate cancer, somatostatin receptor-expressing tumors, like neuroendocrine tumor, epithelial tumors, as well as to methods wherein such compositions are prepared.

Bromocriptine citrate administered to a vertebrate, animal or human, can be used for any purpose including, e.g., the long-term modification and regulation of metabolic disorders, including prediabetes, obesity, insulin resistance, hyperinsulinemia, hyperglycemia and type 2 diabetes mellitus (T2DM) and / or, e.g., the treatment of other medical disorder(s) including immune or endocrine disorders or diseases. Bromocriptine citrate is administered over a limited or extended period at a time of day dependent on re-establishing the normal circadian rhythm of central dopaminergic activity of healthy members of a similar species and sex. Insulin resistance, hyperinsulinemia and hyperglycemia, T2DM, prediabetes, MS or all, can be controlled in humans on a long term basis by such treatment inasmuch as the daily administration of bromocriptine citrate resets neuronal activity timing in the neural centers of the brain to produce long term effects.

The application provides a preparation method and application of oat active peptides for promoting GLP-1 secretion, wherein the oat active peptides contain any one or more of peptide segments NDQRGEII, KQGDVIALPA, PFVQQQQ and PSEQYQPYPEQQEPFVQ. The preparation method of the oat active peptides comprises enzymolysis, chemical synthesis or genetic engineering. The oat active peptides can significantly promote the secretion of GLP-1 by intestinal endocrine cells, and have the advantages of safe and non-toxic side effects, tolerance to gastrointestinal digestive enzyme hydrolysis and easy absorption. The application has simple operation, low requirement for equipment, is suitable for industrial large-scale production, and can be used for the development of new drugs for controlling blood sugar or food for assisting in controlling blood sugar, drugs for controlling body weight or food for assisting in controlling body weight and the like.

The invention belongs to the field of animal model construction, and particularly relates to application of an NFATC2IP gene knockout mouse model. Experiments prove that after the NFATC2IP gene is knocked out, the mouse has the characteristic changes of ovarian weight reduction, volume reduction, estrus cycle disorder, fertility reduction, AMH reduction, FSH increase and the like. It is indicated that the NFATC2IP gene is a key factor for maintaining ovarian reserve and endocrine balance, and an NFATC2IP gene knockout mouse can be used for revealing the occurrence mechanism of ovarian dysfunction and can also be used for screening of novel ovarian protection drugs, research of a hormone regulation mechanism and discovery and verification of biomarkers.

The present disclosure relates to a method of generating pancreatic lineage cells, e.g. islet-like cell aggregates comprising pancreatic beta cells, comprising the steps of providing a single cell suspension of a population of endocrine progenitor cells (EP), allowing the EP cells in the single cell suspension to form 3D structures, and culturing the cells under conditions allowing differentiation into pancreatic mono-hormonal beta cells. The present disclosure also relates to islet-like cell aggregates obtainable by said method and their medical use.

This invention relates to the application of ALKBH5 as a target in the preparation of drugs for inhibiting the progression of TNBC, and to the drugs themselves. This application discovers mRNA m 6 The alpha-modifying demethylase ALKBH5 is specifically highly expressed in triple-negative breast cancer (TNC). Using spontaneous TNC models and xenograft tumor models, knockout or knockdown of ALKBH5 significantly inhibited breast hyperplasia and the development of TNC, and promoted tumor differentiation. Simultaneously, the specific inhibitor EN300-14040 of ALKBH5 significantly inhibited the growth of TNC organoids, promoted TNC cell differentiation, and enhanced the sensitivity of TNC organoids to the endocrine drug 4OH-T, exhibiting a synergistic inhibitory effect with 4OH-T. Therefore, ALKBH5 represents a potential novel therapeutic target for TNC, and ALKBH5 inhibitors are a potential new type of drug for the treatment of TNC.

The generation of complex organ tissues from human embryonic and pluripotent stem cells (PSCs) remains a major challenge for translational studies. It is shown that PSCs can be directed to differentiate into intestinal tissue in vitro by modulating the combinatorial activities of several signaling pathways in a step-wise fashion, effectively recapitulating in vivo fetal intestinal development. The resulting intestinal “organoids” were three-dimensional structures consisting of a polarized, columnar epithelium surrounded by mesenchyme that included a smooth muscle-like layer. The epithelium was patterned into crypt-like SOX9-positive proliferative zones and villus-like structures with all of the major functional cell types of the intestine. The culture system is used to demonstrate that expression of NEUROG3, a pro-endocrine transcription factor mutated in enteric anendocrinosis is sufficient to promote differentiation towards the enteroendocrine cell lineage. In conclusion, PSC-derived human intestinal tissue should allow for unprecedented studies of human intestinal development, homeostasis and disease.

The invention relates to the technical field of biological medicine, and discloses rapamycin-loaded microemulsion gel as well as a preparation method and application thereof. The preparation method of the microemulsion gel comprises the following steps: dissolving N, N-dimethyl octadecyl carboxymethyl chitosan in a water phase, then adding an oil phase, a cosurfactant and rapamycin, and stirring to obtain rapamycin-loaded microemulsion; the preparation method comprises the following steps: dissolving a high polymer material in a PBS solution, heating until the high polymer material is completely dissolved, then adding dopamine, stirring for reaction, and finally dialyzing and freeze-drying to obtain the adhesive. And adding a gel matrix containing a thickening agent and an adhesive into the microemulsion, and stirring to obtain the rapamycin-loaded microemulsion gel. According to the prepared microemulsion gel, transdermal drug delivery of hydrophobic drugs is achieved, testis are coated with the microemulsion gel loaded with rapamycin, the blocking effect of damp-heat stress on differentiation and development of testis interstitial cells can be relieved, and the functionality of a male reproduction endocrine system is recovered.

The invention belongs to the technical field of medical experimental animal models, and particularly relates to a construction method of a rabbit ear acne model for studying acne pathogenesis and drug curative effect. A healthy New Zealand large-ear white rabbit is selected, a testosterone solution is subcutaneously injected to induce endocrine disorder, oleic acid is smeared at an opening of an external auditory canal on the inner side of an ear, dermatobacterium acnes suspension is subcutaneously injected, and whether acne-like lesions such as erythema, papule and comedo appear on the skin of the ear or not is observed. The method is easy and convenient to operate, low in cost, good in repeatability, capable of simulating the pathological process of human acne and suitable for acne pathogenesis research and drug screening.

The present invention provides a method for lowering blood glucose levels in an animal by transplanting a population of pancreatic endocrine precursor cells into an animal.

The invention discloses a fractionation method of an endocrine disrupter in an environmental water body, and belongs to the technical field of water body pollutant analysis. The fractionation method of the endocrine disrupter in the environmental water body comprises the following steps: S1, enriching and concentrating a water sample to obtain a to-be-fractionated liquid; s2, fractionating the to-be-fractionated liquid by adopting an analytical liquid chromatography system and a C18 semi-preparative chromatographic column to obtain fractions. According to the method, high-resolution synchronous fractionation of the endocrine disrupter in a wide polarity range (Log Kw:-0.19-6.62) is realized, the defects of low fractionation efficiency and high solvent consumption of the traditional semi-preparative liquid chromatography are effectively overcome by optimizing a gradient program of an analytical liquid chromatography system, the time and economic cost are saved, and the method is suitable for industrial production. And the fraction can be directly compatible with biological activity test after salting-out-extraction treatment.

The present application provides a kind of metabolism steady state regulation type full nutrition weight loss meal replacement powder, by 82~90 weight parts of endocrine regulation component, 4~8 weight parts of metabolic activation component, 3~5 weight parts of nutrient component and 2~6 weight parts of flavor component, also provides the preparation method of metabolism steady state regulation type full nutrition weight loss meal replacement powder.The present application will realize synchronous intervention to three major core problems of energy metabolism, endocrine coordination, tissue function, reconstructs the metabolic homeostasis of organism, realizes the effective management of body weight.

Disclosed are novel compounds that are antagonists of the human GPR39 protein. Disclosed are pharmaceutical compositions of antagonists of the human GPR39 protein and methods of use. In particular, disclosed herein are methods of using the antagonists to treat diseases or conditions, including cardiovascular conditions, endocrine system and hormone disorders, cancer disorders, metabolic diseases, gastrointestinal and liver diseases, blood disorders, neurological disorders, and respiratory diseases.

The present disclosure relates to a panel of ER regulated genes and method for using the panel for monitoring the response of an individual having cancer to treatment with amcenestrant, the method comprising determining a first ER activity score from a sample from the individual at a first time point before treatment with amcenestrant using the panel, then determining a second ER activity score from a sample from the individual at a second time point following administration of amcenestrant using the panel, and comparing the first ER activity score with the second ER activity score, wherein a decrease in the second ER activity score relative to the first ER activity score is predictive of target engagement of amcenestrant.

The application discloses a human vagina micro-ecological in-vitro model and a construction method and application thereof, and relates to the technical field of medicines.The application discloses a human vagina micro-ecological in-vitro model and a construction method and application thereof.Firstly, a mixed cell group of the vaginal epithelium containing a complete cell lineage and capable of long-term subculture is successfully established, a technical bottleneck that primary vaginal epithelial cells are difficult to expand is solved, and ideal seed cells are provided for model construction.Secondly, a highly-bionic vaginal mucosa model having a tight connection structure, rich layers and an orderly arrangement is constructed, and the physiological barrier and immune regulation functions of the vaginal mucosa are truly simulated.Finally, by introducing lactobacillus symbiosis and confirming the response to estrogen, a multi-element in-vitro research model integrating the anatomical structure of the vagina, resident flora, local immunity and endocrine regulation is constructed, and a reliable technical platform is provided for in-depth exploration of the mechanism of vaginal micro-ecological disorder and efficient screening of related drugs.

This invention relates to a novel use of propargylcysteine ​​in the preparation of anti-mastopathy drugs. The invention discovers that S-propargylcysteine ​​can improve E2 / P imbalance by regulating HPO axis function and inhibiting abnormal activation of the GnRH-sex hormone axis; it also reduces the inflammatory microenvironment by inhibiting the release of inflammatory factors; ultimately, it downregulates ER / PR-mediated proliferation signals and inhibits PCNA expression locally in the breast. Through multi-target regulation of neuroendocrine, inflammatory responses, and proliferation-related signaling pathways, it effectively alleviates breast hyperplasia and its associated chronic stress-induced depressive-like behaviors, thus exerting anti-mastopathy and therapeutic effects on breast hyperplasia complicated with depression.

The application discloses a polypeptide for targeted recognition of a neuroendocrine tumor marker INSM1 and products and applications thereof, and belongs to the fields of molecular imaging and protein polypeptide drug engineering. Specifically, the application relates to development of a polypeptide with high affinity and specificity to a neuroendocrine tumor marker insulinoma-associated protein 1 (INSM1). The application discloses an amino acid sequence of the polypeptide and related applications. The polypeptide is used for labeling and preparation of a polypeptide probe, can be specifically combined with the INSM1 protein, and can be used for in-vivo and in-vitro imaging of neuroendocrine tumors, so as to overcome a diagnosis difficulty caused by a hidden onset of the neuroendocrine tumor and realize early positioning and qualitative diagnosis.

The invention relates to a method of differentiating pancreatic bi-potent progenitor cells into beta cells comprising cultivating pancreatic endocrine precursor cells in a medium that promotes the cAMP signalling pathway that lies downstream of apical-basal polarity in endocrine precursors, which can be used to increase the differentiation of progenitor cells into beta cells. Furthermore, the present invention relates to a method of enriching and / or isolating one or more cells expressing a marker of apical-basal polarity, thereby isolating beta cells, and to a method of producing a population of beta cells from a population of human embryonic stem cells. Furthermore, the present invention relates to a population of beta cells obtainable by the method, a pharmaceutical composition comprising the beta cells, a cell culture of progenitor cells in a medium comprising a cAMP agonist, a complex comprising a beta cell bound by the binding agents specific for CD133 and CD49a, and a use of specific binding partners for isolating beta cells.

The invention relates to the technical field of artificial intelligence and medical health crossing, discloses an endocrine disease AI auxiliary diagnosis and treatment method and system, and aims at solving the problems that in the prior art, multi-source heterogeneous medical data fusion is difficult, model interpretability is poor, personalized modeling capacity is insufficient, and a system lacks a closed-loop feedback mechanism. The method comprises the steps of collecting multi-source heterogeneous medical data of a patient and performing standardization processing; and constructing a unified patient view, inputting the unified patient view into a multi-task deep learning model, and generating a preliminary diagnosis conclusion in combination with knowledge graph information. According to the technical scheme, deep fusion of medical knowledge and data driving is realized, the diagnosis accuracy and the treatment individualization level are improved, the model interpretability and the clinical credibility are enhanced, a sustainable-evolution intelligent diagnosis and treatment ecological system is constructed, and the diagnosis and treatment efficiency and the clinical decision-making quality are remarkably improved.

The current invention is in the field of molecular biology / pharmacology and provides novel 3-oxabicyclo[3.3.1]nonene compounds and derivatives that modulate the effects of the classical estrogen receptors alpha and beta (ERalpha and ERbeta) with little to no biological or physiological effects on the G protein-coupled estrogen receptor GPER (also known as GPR30). These compounds may function as agonists and / or antagonists of one or more of the disclosed classical estrogen receptors. Diseases that are mediated through one or more of these receptors include cancer (including but not limited to breast (particularly endocrine or anti-hormone resistant, and for the prevention / reduction of endocrine or anti-hormone resistance), reproductive and other hormone-dependent cancers, leukemia, colon cancer, prostate cancer), reproductive (genito-urological) including endometritis, prostatitis, polycystic ovarian syndrome, bladder control, hormone-related disorders, hearing disorders, cardiovascular conditions including hot flashes and profuse sweating, hypertension, stroke, obesity, osteoporosis, hematologic diseases, vascular diseases or conditions such as venous thrombosis, atherosclerosis, among numerous others and disorders of the central and peripheral nervous system, including depression, insomnia, anxiety, multiple sclerosis, neuropathy, neurodegenerative disorders (such as Parkinson's disease and Alzheimer's disease), as well as inflammatory bowel disease, Crohn's disease, coeliac (celiac) disease and related disorders of the intestine, among numerous others as described herein. A contraceptive indication to prevent or reduce the likelihood of pregnancy after intercourse is a further aspect of the present invention.

Described herein are compounds that are useful in treating a TYK2-mediated disorder. In some embodiments, the TYK2-mediated disorder is an autoimmune disorder, an inflammatory disorder, a proliferative disorder, an endocrine disorder, a neurological disorder, or a disorder associated with transplantation.

The invention belongs to the technical field of functional compositions, and discloses a composition for dispelling effects of alcohol and protecting liver as well as a preparation method and application thereof, and the composition comprises the following raw materials in percentage by mass: 13-28% of ginseng, 18-28% of globe artichoke, 10-27% of pueraria peptide, 7-12% of houttuynia cordata, 7-9% of mulberry, 6-9% of gardenia and 10-29% of collagen composite peptide. The composition can reduce alcohol irritation, relieve alcohol absorption and increase the alcohol content; meanwhile, the liver and stomach are protected; meanwhile, alcohol metabolism is rapid, hangover is prevented, headache, dizziness, nausea and other uncomfortable symptoms caused by alcohol are relieved, and the drunkenness degree is relieved. After the medicine is taken for 2-6 months, mild fatty liver and moderate fatty liver can be obviously improved, and severe fatty liver and alcoholic liver can be obviously improved; indexes related to endocrine metabolism, such as blood sugar, blood fat, uric acid, triglyceride, total cholesterol, high-density lipoprotein cholesterol, low-density lipoprotein cholesterol, glutamic oxalacetic transaminase and glutamic-pyruvic transaminase, are obviously improved.

This invention is applied in the field of medicine, namely in endocrinology, and can be used in the treatment of type 1 diabetes. The invention proposes a combination containing a dipeptidyl peptidase 4 (DPP-4) inhibitor, a proton pump inhibitor (PP1), and γ-aminobutyric acid or γ-aminobutyric acid receptor agonist. This unique combination and dosage of drugs leads to the regeneration (recovery) of pancreatic β-cells, which occurs with a dramatic reduction in insulin requirements up to a total cessation of insulin in some individuals and is intended for the treatment of type 1 diabetes mellitus.

The disclosure provides methods for the use of gene expression measurements to classify or identify neuroendocrine cancer in samples obtained from a subject in a clinical setting, such as in cases of formalin fixed, paraffin embedded (FFPE) samples.

The invention provides an essential oil composition for improving sleep quality, and relates to the field of plant essential oils, the essential oil composition comprises the following raw materials by mass: 15-20% of rose geranium essential oil, 15-20% of organic lavender essential oil, 30-40% of organic Provenus lavender essential oil, 15-20% of organic Atlantic cedar essential oil, and 10-15% of West Indian sandalwood essential oil. The essential oil composition is used for improving sleep, chemical components of different essential oils complement and cooperate, and a composite effect is achieved on multiple aspects of central nervous system sedation, emotion stabilization, endocrine balance, vegetative nerve regulation and the like.

The invention relates to the field of information systems and cloud platforms for interaction detection of proteins and metabolites and health correlation in biological material test and analysis, and discloses a short figure development multi-dimensional data fusion evaluation system based on an intestinal brain liver axis quantitative model. Comprising a data acquisition module, an axial gating mapping module and a growth steady state evaluation module, and the data acquisition module acquires an intestinal metabolism component, a liver growth axis component and a neuroendocrine component of a subject; the axial gating mapping module is used for determining signal transduction time delay, calling an intestinal metabolism component at the T-tau moment as a parameter reference through asynchronous offset processing, and determining a gating calibration coefficient in combination with a neuroendocrine component fluctuation slope; and the growth steady state evaluation module performs gain compensation on the liver growth axis component according to the calibration coefficient and outputs a growth and development evaluation index. According to the invention, asynchronous interference of biochemical signal circulation is solved, evaluation model drift caused by phase dislocation is eliminated, and the accuracy of development blocking reason screening is enhanced.

A method for treating neuroendocrine tumors that overexpress somatostatin receptors is provided. [Solution] The present invention relates to a method for treating cancers that overexpress somatostatin receptors. More specifically, the present invention provides a combination therapy in which a combination of peptide receptor radionuclide therapy (PRRT) and immuno-oncology therapy (IO therapy) is administered for the treatment of neuroendocrine tumors. In a specific embodiment, the PRRT is [177]lutetium-DOTA[O]-Tyr[3]-octreotate, and the IO therapy comprises administering an inhibitor that inhibits the PD-1 / PD-L1 and CTLA-4 pathways.